Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

920
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
920
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

51
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
51
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

48
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
48
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

307
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
307
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.1K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.1K
Angina IV: Management01:26

Angina IV: Management

38
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
38

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America.

Journal of clinical lipidology·2024
Same author

The role of ceramides in the disruption of the cutaneous permeability barrier, a common manifestation of skin disorders.

Journal of lipid research·2024
Same author

Multifactorial chylomicronemia syndrome.

Current opinion in endocrinology, diabetes, and obesity·2023
Same author

Lipid-lowering in diabetes: An update.

Atherosclerosis·2023
Same author

Serum amyloid A and metabolic disease: evidence for a critical role in chronic inflammatory conditions.

Frontiers in cardiovascular medicine·2023
Same author

Recent advances in lipidology.

Best practice & research. Clinical endocrinology & metabolism·2023

Related Experiment Video

Updated: Sep 25, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Approach to patients with elevated low-density lipoprotein cholesterol levels.

Kenneth R Feingold1, Alan Chait2

  • 1University of California San Francisco, San Francisco, CA, USA.

Best Practice & Research. Clinical Endocrinology & Metabolism
|April 29, 2022
PubMed
Summary

Lowering elevated low-density lipoprotein cholesterol (LDL-C) significantly reduces atherosclerotic cardiovascular disease (ASCVD) risk. Early and aggressive LDL-C reduction offers greater ASCVD benefits, especially at higher levels and risk scores.

Keywords:
PCSK9 inhibitorsatherosclerotic cardiovascular diseaseezetimibelow-density lipoprotein cholesterolstatins

More Related Videos

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
07:26

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

111
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.6K

Related Experiment Videos

Last Updated: Sep 25, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
07:26

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

111
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.6K

Area of Science:

  • Cardiology and Lipidology
  • Preventive Medicine
  • Clinical Practice Guidelines

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Identifying contributing factors to high LDL-C, including lifestyle, comorbidities, medications, and genetics, is crucial for effective management.
  • Existing clinical guidelines for LDL-C reduction show some discordance in recommendations.

Purpose of the Study:

  • To present key principles for guiding clinical decisions on initiating and intensifying LDL-C lowering therapy.
  • To synthesize evidence supporting the benefits of early and more substantial LDL-C reductions.
  • To aid clinicians in optimizing treatment strategies for patients with elevated LDL-C and varying ASCVD risk.

Main Methods:

  • Review of current scientific literature and clinical guidelines concerning LDL-C management.
  • Analysis of evidence linking LDL-C levels, treatment timing, and magnitude of reduction to ASCVD risk.
  • Synthesis of principles to inform clinical decision-making in diverse patient populations.

Main Results:

  • Evidence strongly supports that earlier initiation of LDL-C lowering therapy leads to better outcomes.
  • Greater reductions in LDL-C levels correlate with more significant decreases in ASCVD risk.
  • The benefits of LDL-C lowering treatment are amplified in individuals with higher baseline LDL-C levels and elevated ASCVD risk.

Conclusions:

  • Implementing evidence-based principles can enhance the effectiveness of LDL-C management strategies.
  • Personalized treatment decisions should prioritize early and aggressive LDL-C reduction based on individual risk profiles.
  • These principles aim to improve patient outcomes by optimizing the approach to lowering LDL-C and mitigating ASCVD risk.